Bioxyne Limited, a life sciences and health products company, researches, develops, manufactures, markets, and distributes consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus Fermentum PCC.
The last earnings update was 37 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Bioxyne. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Bioxyne's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bioxyne has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Personal Products industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Bioxyne's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Bioxyne's earnings growth to the Australia market average as no estimate data is available.
Unable to compare Bioxyne's revenue growth to the Australia market average as no estimate data is available.
Unable to determine if Bioxyne is high growth as no earnings estimate data is available.
Unable to determine if Bioxyne is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Bioxyne's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Nam Hoat Chua, BA has been the Chief Executive Officer and Managing Director of Bioxyne Limited since June 13, 2017. Mr. Chua served as Vice President of Asia Operations of New Image Group Limited for over 10 years and served as its Executive Director since March 24, 2010. Mr. Chua has over 33 years experience in the direct selling industry and is highly regarded for his ability to develop leadership and establish successful infrastructures in countries. Mr. Chua commenced his direct sales career in 1985 when he successfully launched First Image Sdn Bhd in Malaysia which became a successful retailing company selling the Total Image brand of Health Care Products. In 1989, he has set up Abric Image Sdn Bhd. He has been a Director of Bioxyne Limited since April 2017. Mr. Chua is fluent in Malay, Indonesian, Mandarin and several other dialects of Chinese. He holds a BA in economics and commerce from the University of Toronto.
Nam's compensation has increased whilst company is loss making.
Nam's remuneration is about average for companies of similar size in Australia.
Management Team Tenure
Average tenure of the
management team in years:
The tenure for the Bioxyne management team is about average.
MD, CEO & Director
CFO & Company Secretary
Chief Scientific Officer and Director of Research & Development
Board of Directors Tenure
Average tenure of the
board of directors in years:
The tenure for the Bioxyne board of directors is about average.
Board of Directors
MD, CEO & Director
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Bioxyne Limited, a life sciences and health products company, researches, develops, manufactures, markets, and distributes consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus Fermentum PCC. The company operates through Wholesale Sales and Direct Sales segments. It also engages in developing a range of functional foods and beauty products. The company’s products portfolio include BK18, a dairy based food supplement; Allura, a beauty drink with soy protein and apple fibre, and marine collagen extract for women’s weight management; Mustang, a nutritional shake for men’s weight management; Mymana, a colostrum and honey based dairy formula product; and BEssence, an anti-ageing serum. In addition, it offers its probiotic products under the Progastrim and proTract names. The company provides its products online, as well as through retail channels in Australia, the United States, New Zealand, and Asia. Bioxyne Limited is headquartered in Sydney, Australia.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.